Australia markets open in 2 hours 45 minutes
  • ALL ORDS

    6,905.30
    +248.90 (+3.74%)
     
  • AUD/USD

    0.6501
    -0.0018 (-0.28%)
     
  • ASX 200

    6,699.30
    +242.40 (+3.75%)
     
  • OIL

    86.10
    +2.47 (+2.95%)
     
  • GOLD

    1,733.60
    +31.60 (+1.86%)
     
  • BTC-AUD

    31,039.62
    +755.86 (+2.50%)
     
  • CMC Crypto 200

    457.71
    +12.28 (+2.76%)
     

2 Reasons This Beaten-Down Stock Could Be About to Rebound

·4-min read
2 Reasons This Beaten-Down Stock Could Be About to Rebound

Gilead Sciences (NASDAQ: GILD) has kept its revenue and earnings growing in the past two years -- if ever so slightly -- largely thanks to Veklury, its COVID-19 therapy. Gilead Sciences' revenue rose by only about 1% year over year to $6.3 billion during the period. Excluding sales of Veklury, which dropped by 46% year over year to $445 million, Gilead Sciences' revenue for the quarter grew by a more impressive and respectable (by industry standards) 7%.